Cargando…

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology

BACKGROUND: The concept of personalized medicine defines a promising approach in cancer care. High-throughput genomic profiling of tumor specimens allows the identification of actionable mutations that potentially lead to tailored treatment for individuals’ benefit. The aim of this study was to prov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prager, Gerald W., Unseld, Matthias, Waneck, Fredrik, Mader, Robert, Wrba, Fritz, Raderer, Markus, Fuereder, Thorsten, Staber, Phillip, Jäger, Ulrich, Kieler, Markus, Bianconi, Daniela, Hoda, Mir Alireza, Baumann, Lukas, Reinthaller, Alexander, Berger, Walter, Grimm, Christoph, Kölbl, Heinz, Sibilia, Maria, Müllauer, Leonhard, Zielinski, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398177/ https://www.ncbi.nlm.nih.gov/pubmed/30847023 http://dx.doi.org/10.18632/oncotarget.26604

Ejemplares similares

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
por: Unseld, Matthias, et al.
Publicado: (2018)

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
por: Kieler, Markus, et al.
Publicado: (2019)

Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
por: Kieler, Markus, et al.
Publicado: (2017)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
por: Kieler, Markus, et al.
Publicado: (2020)

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
por: Unseld, Matthias, et al.
Publicado: (2020)

Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior
por: Bianconi, Daniela, et al.
Publicado: (2022)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
por: Bianconi, Daniela, et al.
Publicado: (2017)

Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
por: Balendran-Braun, Sukirthini, et al.
Publicado: (2021)

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
por: Aust, Stefanie, et al.
Publicado: (2020)

Molecularly guided treatment of metastatic parotid gland carcinoma in adults
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2017)

PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients
por: Minichsdorfer, Christoph, et al.
Publicado: (2019)

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer
por: Bartl, Thomas, et al.
Publicado: (2023)

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients
por: Grech, Christina T., et al.
Publicado: (2022)

Review of cancer treatment with immune checkpoint inhibitors: Current concepts, expectations, limitations and pitfalls
por: Thallinger, Christiane, et al.
Publicado: (2017)

Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease
por: Kieler, Markus, et al.
Publicado: (2016)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

The impact of COVID‐19 on cancer care of outpatients with low socioeconomic status
por: Zeilinger, Elisabeth L., et al.
Publicado: (2022)

Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients
por: Kiesewetter, Barbara, et al.
Publicado: (2014)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Bartl, Thomas, et al.
Publicado: (2021)

RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2019)

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
por: Taghizadeh, Hossein, et al.
Publicado: (2022)

Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
por: Prager, Gerald W, et al.
Publicado: (2014)

CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior
por: Poettler, Marina, et al.
Publicado: (2013)

Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients
por: Zeilinger, Elisabeth L., et al.
Publicado: (2022)

Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
por: Oberndorfer, Felicitas, et al.
Publicado: (2021)

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2016)

Applied precision cancer medicine in metastatic biliary tract cancer
por: Taghizadeh, H., et al.
Publicado: (2020)

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
por: Anker, Markus S., et al.
Publicado: (2020)

Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy
por: Danzinger, Sabine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5v03piijpf9jjp4sarsu5amt5d